|
Products |
| Products |
|
Diseases |  |
News |  |
| «12...2728293031323334353637...39313932» |
- Opdivo (nivolumab) / BMS
Nivolumab (NIVO) plus gemcitabine-cisplatin (GC) vs GC alone in Asian patients with previously untreated unresectable or metastatic urothelial carcinoma (u/mUC) from CheckMate 901 (Hall 404) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1168;
- Keytruda (pembrolizumab) / Merck (MSD), Padcev (enfortumab vedotin-ejfv) / Astellas, Pfizer
Enfortumab Vedotin plus Pembrolizumab (EV+P) Vs chemotherapy (Chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Pan-Asian Subgroup analysis from EV-302/KEYNOTE-A39 (Hall 404) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1167;
- Inlyta (axitinib) / Pfizer, Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
Serum amyloid a promotes resistance to neoadjuvant toripalimab plus axitinib in renal cell carcinoma with venous tumor thrombus (Hall 404) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1164;
- Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Five-year overall survival (OS) and OS by baseline liver function from the Phase 3 HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) (Hall 406) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1159;
- Opdivo (nivolumab) / BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD), Yervoy (ipilimumab) / BMS
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW Asian subgroup analysis (Hall 406) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1158;
- BPI-371153 / Betta Pharma
A first-in-human, phase I study of BPI-371153, a novel small-molecule PD-L1 inhibitor, in advanced solid tumors or recurrent/refractory (r/r) lymphoma (Hall 402) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1153;
- ABSK043 / Abbisko
Updated Results of Oral PD-L1 Inhibitor ABSK043 in Advanced Solid Tumor Patients (pts) from a Phase 1 Study (Hall 402) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1152;
- Kisqali (ribociclib) / Novartis
Analysis of Asian and non-Asian patients (pts) from the NATALEE trial of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in pts with HR+/HER2? early breast cancer (EBC) (Hall 404) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1144;
- Rituxan (rituximab) / Roche
Relapsed Mantle Cell Lymphoma with Complete Metabolic Response on Rituximab Gemcitabine-Oxaliplatin. Treatment in a Resource Limited Setting in the Philippines, A Case Report (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1113;
- Darzalex (daratumumab) / J&J
Analyses of Long-term safety and blood levels of daratumumab in patients with multiple myeloma after switching from intravenous to subcutaneous administration (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1081;
- Tyvyt (sintilimab) / Eli Lilly
TiP: Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy with Cryoablation in the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1015;
- Enweida (envafolimab) / 3DMed, Tracon Pharma, Ascletis
Second-line envafolimab and beyond in locally advanced or metastatic non-small cell lung cancer (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_988;
- Keytruda (pembrolizumab) / Merck (MSD)
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_987;
- Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, JCXH-212 / Immorna
A phase I study of a common neoantigen srRNA vaccine (JCXH-212) with or without toripalimab in patients with non-small cell lung cancer(NSCLC) (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_977;
- Hansizhuang (serplulimab) / Fosun Pharma
First-Line Serplulimab for Advanced Squamous Non-Small Cell Lung Cancer: A Multicenter, Single-Arm, Real-World ASTRUM-004R Study (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_975;
- Imfinzi (durvalumab) / AstraZeneca
Low-dose Durvalumab in Combination with Etoposide and Platinum as First-line Treatment of Patients with Extensive-stage Small Cell Lung Cancer - a Multi-Institutional study from India (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_972;
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
NEJ053C: A phase II study of nivolumab and ipilimumab combined with chemotherapy after lung stereotactic body radiotherapy as first-line therapy for stage IV non-small cell lung cancer (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_969;
- Opdivo (nivolumab) / BMS
Association between the administration time and therapeutic effect of nivolumab in patients with non-small cell lung cancer : A multicenter retrospective observational study (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_965;
- AiRuiKa (camrelizumab) / HLB Bio Group
First-Line Camrelizumab Plus Chemotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Controlled Trial (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_959;
- Imfinzi (durvalumab) / AstraZeneca, Tecentriq (atezolizumab) / Roche
Cisplatin (CDDP)+Etoposide (ETP)+Durvalumab (DUR) vs. Carboplatin (CBDCA)+ETP+Atezolizumab (ATZ): propensity score matching (PSM) real-world data (RWD) on CDDP-fit extensive disease (ED)-small cell lung cancer (SCLC) (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_956;
- Imfinzi (durvalumab) / AstraZeneca, Tecentriq (atezolizumab) / Roche
Comparison of atezolizumab/etoposide/platinum and durvalumab/etoposide/platinum for extensive-stage small cell lung cancer in Japan: A multicenter retrospective observational study. (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_955;
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Efficacy and safety of first-line ipilimumab and nivolumab treatment in elderly patients with non-small cell lung cancer (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_947;
- Kaitanni (cadonilimab) / Akesobio, Focus V (anlotinib) / Advenchen, Sino Biopharm
A phase Ib/II study of second-line cadonilimab, anlotinib and docetaxel in patients with checkpoint inhibitor (CPI)-experienced advanced non-small cell lung cancer (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_940;
- Avastin (bevacizumab) / Roche, iparomlimab/tuvonralimab (PSB205) / Sound Biologics, Qilu Pharma
Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for epidermal growth factor receptor inhibitor (EGFRi)-resistant, EGFR-mutant, advanced non-small cell lung cancer (NSCLC): Updated results from Cohort 5 in the DUBHE-L-201 study (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_939;
- Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, tifcemalimab (TAB004) / Shanghai Junshi Biosci
Tifcemalimab combined with toripalimab and docetaxel as 2nd line treatment for immunotherapy-treated squamous cell non-small cell lung cancer (Sq-NSCLC) patients: A phase Ib/II study (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_937;
- Imfinzi (durvalumab) / AstraZeneca
A phase II study of irinotecan-cisplatin plus durvalumab for untreated extensive-stage small cell lung cancer (WJOG13520L, REBORN trial) (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_932;
- tiragolumab (RG6058) / Roche, Tecentriq (atezolizumab) / Roche
SKYSCRAPER-02C: phase 3 study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC) in China (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_929;
- Tecentriq (atezolizumab) / Roche
Whole exome sequencing (WES) analyses from IMpower133 and 6-year (y) overall survival (OS) from IMbrella A in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with atezolizumab (atezo) (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_927;
- Tevimbra (tislelizumab-jsgr) / BeiGene
RATIONALE-304 Long-term Outcomes: First-line Tislelizumab (TIS) + Chemotherapy (chemo) vs Chemo for Locally Advanced or Metastatic Nonsquamous (NSQ) NSCLC (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_925;
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Exploratory Biomarker Analysis in EGFR mutated NSCLC Patients who treated with Atezolizumab plus Bevacizumab and Chemotherapy from Phase III ATTLAS trial (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_924;
- Imfinzi (durvalumab) / AstraZeneca
Comparison of biweekly carboplatin plus nab-paclitaxel with concurrent radiotherapy followed by durvalumab consolidation in elderly and younger patients. (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_917;
- Keytruda (pembrolizumab) / Merck (MSD)
Pembrolizumab with Radiotherapy versus Pembrolizumab Alone in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_916;
- Imfinzi (durvalumab) / AstraZeneca
Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101) (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_913;
- Opdivo (nivolumab) / BMS
"Evaluation of low dose Nivolumab with Neoadjuvant chemotherapy in non small cell lung cancer : a phase II open label randomised clinical trial (ELON)" (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_909;
- AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab plus platinum doublet chemotherapy as adjuvant treatment of stage IIA-IIIA non-small cell lung cancer:a phase II, single-arm research (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_905;
- Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib Combined with Sintilimab Versus Chemotherapy Combined with Immunotherapy in Perioperative NSCLC: A Phase II Study (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_895;
- Opdivo (nivolumab) / BMS
Perioperative nivolumab (NIVO) in patients (pts) with resectable stage II (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_890;
- Ibrance (palbociclib) / Pfizer
Analyses of risk factors for adverse events with palbociclib and the association between adverse events occurrence and survival (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_845;
- Cosela (trilaciclib) / G1 Therap
Multiple Cohort, Open-Label, Exploratory Clinical Study of Trilaciclibe for CIM in Combination with Chemotherapy in First-line Treatment of Advanced Solid Tumors-Interim Data Analysis (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_779;
- Opdivo (nivolumab) / BMS
Exploring the Efficacy of Low-Dose Nivolumab in Metastatic Settings (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_778;
- Enweida (envafolimab) / 3DMed, Tracon Pharma, Ascletis
A single-arm, phase II study of envafolimab combined with chemoradiotherapy and recombinant human endostatin in high-risk locally advanced nasopharyngeal carcinoma (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_769;
- Keytruda (pembrolizumab) / Merck (MSD)
Evaluating the efficacy and safety of pembrolizumab in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter, retrospective study analysis (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_757;
- Opdivo (nivolumab) / BMS
Real-world data of nivolumab efficacy for treatment of recurrent or metastatic head and neck squamous cell carcinoma. (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_751;
- Opdivo (nivolumab) / BMS
Low-Dose Nivolumab six weekly plus Triple Metronomic Chemotherapy in Advanced Head and Neck Cancer-A prospective, Open Label Single Centre Study from Eastern India (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_750;
- Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Erbitux (cetuximab) / Eli Lilly
Updated results of toripalimab combined with cetuximab in PD-L1 positive untreated recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase Ib/II study (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_728;
- Kaitanni (cadonilimab) / Akesobio
A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with chemotherapy for the treatment of anti-PD-1 resistant, recurrent, or metastatic nasopharyngeal carcinoma (R/M NPC) (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_726;
- Tevimbra (tislelizumab-jsgr) / BeiGene
Preliminary safety and efficacy results from phase II study pulsed radiotherapy with tislelizumab in patients with recurrent Head & Neck Cancer (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_725;
- Avastin (bevacizumab) / Roche, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
Adebrelimab Plus Chemotherapy and Bevacizumab Induction Therapy Followed by Maintenance Therapy with Adebrelimab Plus Fluzoparib and Bevacizumab in Platinum-Sensitive Relapsed Ovarian Cancer (CHANGCHUN): A Single-Arm, Exploratory Study (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_723;
- Jemperli (dostarlimab-gxly) / GSK
Real-world outcome of dostarlimab in dMMR/MSI-H advanced/recurrent endometrial cancer: Updated results from Korean expanded access program (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_719;
- Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Aidixi (disitamab vedotin) / Pfizer
A prospective, single-arm clinical study of Disitamab Vedotin (DV) combined with Toripalimab for kidney sparing in solitary kidney or renal insufficiency or bilateral multiple upper urinary tract urothelial carcinoma (UTUC) (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_670;